Inventor · disambiguated record
Nils Langeland Johansen
Also filed as: JOHANSEN NILS L · JOHANSEN NILS LANGELAND
19 granted patents·22 pending applications·459 citations·filing 1981–2020
95Inventor score
Files withNOVO NORDISK AS20NOVO NORDISK HEALTHCARE AG13BEHRENS CARSTEN2JOHANSEN NILS LANGELAND2LAU JESPER1
Top patents by PatentIndex Score
41 records- 0195US7524813B2Selectively conjugated peptides and methods of making the sameNOVO NORDISK HEALTHCARE AG·Filed 2006·Granted Apr 28, 2009·72 cites·3 claims
- 0292US8779109B2Growth hormones with prolonged in-vivo efficacyNOVO NORDISK HEALTHCARE AG·Filed 2013·Granted Jul 15, 2014·17 cites·11 claims
- 0392US7411039B2GLP-2 compounds, formulations, and uses thereofNOVO NORDISK AS·Filed 2003·Granted Aug 12, 2008·69 cites·31 claims
- 0489US7432352B2Hybrid molecules having Factor VII/VIIa activityNOVO NORDISK HEALTHCARE AG·Filed 2006·Granted Oct 7, 2008·16 cites·9 claims
- 0588US6013658ACompounds with growth hormone releasing propertiesNOVO NORDISK AS·Filed 1997·Granted Jan 11, 2000·68 cites·4 claims
- 0685US8841249B2Growth hormones with prolonged in-vivo efficacyJOHANSEN NILS LANGELAND·Filed 2010·Granted Sep 23, 2014·9 cites·4 claims
- 0783US7517854B2Melanocortin receptor agonistsNOVO NORDISK AS·Filed 2006·Granted Apr 14, 2009·9 cites·31 claims
- 0881US9920106B2GLP-1 compoundsJOHANSEN NILS LANGELAND·Filed 2012·Granted Mar 20, 2018·6 cites·43 claims
- 0977US8865868B2Conjugated proteins with prolonged in vivo efficacyBEHRENS CARSTEN·Filed 2009·Granted Oct 21, 2014·4 cites·9 claims
- 1077US5990084ACompounds with growth hormone releasing propertiesNOVO NORDISK AS·Filed 1997·Granted Nov 23, 1999·44 cites·77 claims
- 1176US5767085ACompounds with growth hormone releasing propertiesNOVO NORDISK AS·Filed 1994·Granted Jun 16, 1998·38 cites·18 claims
- 1275US2020102568A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2019·Application pending·0 cites
- 1372US5998375ANociceptin analoguesNOVO NORDISK AS·Filed 1998·Granted Dec 7, 1999·44 cites·72 claims
- 1470US9695226B2Growth hormones with prolonged in-vivo efficacyBEHRENS CARSTEN·Filed 2011·Granted Jul 4, 2017·1 cites·14 claims
- 1565US6127341ACompounds with growth hormone releasing propertiesNOVO NORDISK AS·Filed 1998·Granted Oct 3, 2000·28 cites·21 claims
- 1665US2020306382A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2020·Application pending·0 cites
- 1765US2007105770A1Transglutaminase mediated conjugation of peptidesNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 1863US2009264366A1Transglutaminase Mediated Conjugation of PeptidesNOVO NORDISK HEALTHCARE AG·Filed 2009·Application pending·0 cites
- 1963US2019203213A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2019·Application pending·0 cites
- 2060US5854211ACompounds with growth hormone releasing propertiesNOVO NORDISK AS·Filed 1994·Granted Dec 29, 1998·15 cites·15 claims
- 2160US2013040884A1Albumin-binding conjugates comprising fatty-acid and pegNOVO NORDISK AS·Filed 2012·Application pending·0 cites
- 2260US2014329750A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2014·Application pending·0 cites
- 2360US2007203058A1Novel Glp-1 DerivativesNOVO NORDISK AS·Filed 2004·Application pending·0 cites
- 2459US2013053315A1Novel glp-1 derivativesLAU JESPER·Filed 2012·Application pending·0 cites
- 2558US2016355859A1Transglutaminase mediated conjugation of peptidesNOVO NORDISK HEALTHCARE AG·Filed 2016·Application pending·0 cites
- 2658US2017239362A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2017·Application pending·0 cites
- 2757US2018221501A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2017·Application pending·0 cites
- 2857US2009253166A1Conjugation of PeptidesNOVO NORDISK AS·Filed 2009·Application pending·0 cites
- 2955US2010305032A1Novel GLP-1 DerivativesNOVO NORDISK AS·Filed 2010·Application pending·0 cites
- 3052US2007042956A1Novel GLP-1 compoundsNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 3152US2011263501A1Growth Hormone Conjugate with Increased StabilityNono Nordisk Health Care AG·Filed 2009·Application pending·0 cites
- 3251US6350767B1Compounds with growth hormone releasing propertiesNOVO NORDISK AS·Filed 1999·Granted Feb 26, 2002·8 cites·11 claims
- 3350US2016017017A1Growth Hormone CompoundsZHAO XIN·Filed 2014·Application pending·0 cites
- 3447US2010009917A1Modulating Enzymatic Processes by Addition of Diolcontaining SubstancesNOVO NORDISK HEALTHCARE AG·Filed 2008·Application pending·0 cites
- 3544US2009117640A1Transglutaminase Variants with Improved SpecificityNOVO NORDISK HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 3643US2006105948A1GLP-2 derivativesNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 3741US2008182783A1Growth Hormone ConjugatesNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 3840US2008064630A1Osteogenic Growth Peptide Fusion ProteinsNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 3939US11292825B2Protein conjugatesNOVO NORDISK AS·Filed 2016·Granted Apr 5, 2022·0 cites·16 claims
- 4039US4598065AUse of peptides as medicaments and certain novel peptidesNOVO INDUSTRI AS·Filed 1981·Granted Jul 1, 1986·6 cites·4 claims
- 4135US6011006AMethod of treating hot flushes with hexapeptidesNOVO NORDISK AS·Filed 1999·Granted Jan 4, 2000·5 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Nils Langeland Johansen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →